AMY NELSON: Open Payments
NPI 1144831579 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,636 in 197 payments from 16 companies in 2025. Trend: 2023 $1,030 · 2024 $1,590 · 2025 $3,636
Food & beverage: $3,598Education: $39
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $715 |
| Otsuka America Pharmaceutical, Inc. | 27 | $529 |
| Axsome Therapeutics, Inc. | 22 | $455 |
| Neurocrine BioSciences, Inc. | 13 | $345 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $323 |
| Janssen Pharmaceuticals, Inc | 9 | $253 |
| Teva Pharmaceuticals USA, Inc. | 12 | $242 |
| Alkermes, Inc. | 10 | $171 |
| Vanda Pharmaceuticals Inc. | 9 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $147 |
Products named: VRAYLAR, REXULTI, Auvelity, INGREZZA, CAPLYTA, AUSTEDO XR, INVEGA SUSTENNA, FANAPT.
Industry payments across TX — which companies pay providers there.
